NCT00708292View on ClinicalTrials.gov

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG

AUY922

DRUG

Bortezomib

DRUG

Dexamethasone

Trial Locations (9)

3004

Novartis Investigative Site, Melbourne

28006

Novartis Investigative Site, Madrid

60590

Novartis Investigative Site, Frankfurt

78229

Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3), San Antonio

81675

Novartis Investigative Site, München

85259

Mayo Clinic - Arizona Cancer Clinical Research Unit, Scottsdale

97070

Novartis Investigative Site, Würzburg

169608

Novartis Investigative Site, Singapore

08036

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY